|Articles|December 1, 2000

New Approaches for the Diagnosis and Management of Alzheimer's Disease
Volume 6
Issue 22 Suppl

The Pharmacoeconomics of Alzheimer's Disease

Author(s)Howard Fillit, MD

Download PDF: The Pharmacoeconomics of Alzheimer's Disease

Articles in this issue

over 25 years ago

Article

Participating Faculty

over 25 years ago

Article

Introduction

over 25 years ago

Article

Screening and Early Diagnosis of Dementia

over 25 years ago

Article

Alzheimer's Disease: Clinical Treatment Options

over 25 years ago

Article

Managed Care Decisions in Alzheimer's Disease

over 25 years ago

Article

Conflicting Priorities in Alzheimer's Care, Primary Care, and Managed Care: Who Pays the Price?

over 25 years ago

Article

Continuing Medical Education Quiz

over 25 years ago

Article

Selected Abstracts

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Health care costs | Image Credit: © Valeri Luzina - stock.adobe.com

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

ByPooja Chandrashekar, MD, MBA,Sachin H. Jain, MD, MBA

June 4th 2026

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

ByAllison Spitery, PharmD, BCACP,Alison Lobkovich, PharmD, BCACP,Emily Thomas, PharmD, BCPS, BCACP

June 4th 2026

The Pharmacoeconomics of Alzheimer's Disease

Articles in this issue

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

Trending on AJMC

What ADA 2026 Data Reveal About the Growing Gap in Ketone Monitoring: Eden Miller, DO

GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis

Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss

GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale

Childhood Influenza Vaccine Rates Decreased From 2017 to 2023